Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study

Lead Sponsor:

Flanders Medical Research Program

Collaborating Sponsors:

Spectranetics Corporation

Conditions:

Peripheral Arterial Occlusive Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

This investigation is designed to assess the immediate and long-term angiographic patency outcomes of excimer laser recanalisation followed by PTA in the treatment of long (\>50 mm) infrapopliteal les...

Eligibility Criteria

Inclusion

  • The treatment vessel is DeNovo
  • Stenotic (\>50%) or occlusive atherosclerotic disease of infrapopliteal artery(s)
  • Length of target lesion is \> 50 mm
  • Reference target vessel diameter between 2-4.0 mm by visual assessment
  • Documented Rutherford Class 4 or 5 symptomatic critical limb ischemia
  • The patient must be \>18 years of age
  • Life-expectancy of more than 12 months
  • The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure
  • The patient must be willing and able to return to the appropriate follow-up times for the duration of the study
  • The patient must provide written patient informed consent that is approved by the ethics committee
  • Anatomic Inclusion Criteria
  • All inflow lesions successfully (\<30 residual stenosis) treated prior to target lesion treatment during same procedure or according standard of care without unresolved complications
  • At least one angiographically visible target at the ankle for establishment of straight line flow.

Exclusion

  • Patient refusing treatment
  • The target vessel segment diameter is not suitable for available catheter design.
  • Unsuccessfully treated endovascular or bypass( \>30% residual stenosis) proximal ( iliac, SFA, popliteal) inflow limiting arterial/graft stenosis
  • Lesion lies within or adjacent to an aneurysm
  • The patient has a known allergy to heparin, Aspirin or other antiaggregant therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
  • The patient has a history of prior life-threatening contrast media reaction.
  • The patient is currently enrolled in another investigational device or drug trial.
  • The patient is currently breast-feeding, pregnant or intends to become pregnant.
  • The patient is unable to provide informed consent
  • The patient has end stage renal disease (currently on any form of dialysis)
  • Known Left Ventricular Ejection Fraction \< 35%
  • The patient has had an MI within 30 days prior to enrollment
  • The patient has had a CVA within 90 days prior to enrollment
  • Serum Creatinine \> 150 µmol
  • The patient has a previous bypass in the target limb
  • The patient has a current systemic infection

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2009

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00718991

Start Date

July 1 2008

End Date

July 1 2009

Last Update

March 9 2015

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Imelda Hospital

Bonheiden, Belgium, 2820

2

AZ St-Blasius

Dendermonde, Belgium, 9200